Why the study?
Does growth hormone therapy affect serum IGFBP-4 levels in children with endocrinologic disorders?
Does growth hormone therapy affect serum IGFBP-4 levels in children with endocrinologic disorders?
Serum IGFBP-4 levels are influenced by growth hormone and sex steroids, and its dynamics may predict or contribute to the response to GH therapy in children.
IGFBP-4 dynamics were associated with GH response in children; hypothesis-generating for biomarker utility, needing prospective validation.
IGFBP-4 is a 24kD protein, originally isolated from the conditioned medium of human bone cells, and has been implicated as a potent inhibitor of IGF action in vitro. To clarify its biological functions in human bone, I measured the serum concentration of IGFBP-4 from patients with endocrinologic disorders, using Western immunoblot.In normal children, IGFBP-4 increased with age. The serum IGFBP-4 levels of patients with GH deficiency and panhypopituitarism were lower than those of normal children. In addition, the serum levels of IGFBP-4 were also significantly lower in children with Turner's syndrome than in the age-matched normal children who were post pubertal. These findings suggest that GH and the sex steroid increase the production of serum IGFBP-4.Then, I examined the influence of GH on the serum level of of IGFBP-4. In the good responders to GH therapy, IGFBP-4 decreased rapidly during the first month, continued to decrease until the third month, and then increased slowly. On the contrary, in the poor responders to GH therapy, the IGFBP-4 level increased until the third month and then remained at a high level. The increased serum IGFBP-4 level may, at least in part, contribute to the low response to GH therapy in the poor responders.
No takes yet. Share an insight, caveat, or question.
Yoshitaka Yamanaka (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: